Drug · CHEMBL108
CARBAMAZEPINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CARBAMAZEPINE. Drugs and targets, record CHEMBL108. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL108
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Arbil mr, Carbagen sr, Carbatrol, Carnexiv, Epimaz, Epimaz ret, Epitol, Equetro, Sirtal ret, Tegretol, Tegretol chewtab, Tegretol prolonged release, Tegretol xr, Tegretol-xr, Teril, Teril ret, Timonil 200 ret, Timonil 400 ret
- ChEMBL
- Other names
Biston, Carbamazepina, Carbamazepine anhydrous, Carbamazepine extended release, Carbamazepinum, Finlepsin, G-32883, GEIGY 32883, Karbamazepin, Karbelex, NSC-169864, Neurotol, Neurotop, Sirtal, Stazepine, Tegretal, Telesmin, Timonil
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 20 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets10
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6336 |
| SCN11A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/11280 |
| SCN1A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6323 |
| SCN2A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6326 |
| SCN3A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6328 |
| SCN4A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6329 |
| SCN5A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6331 |
| SCN7A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6332 |
| SCN8A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6334 |
| SCN9A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6335 |
Source ChEMBL
Diseases20
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 20Source Open Targets
See all 20 diseasesTrials129
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01243177 | Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older | Phase 3 | 888 | 2016-02-23 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT00477295 | A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy | Phase 3 | 583 | 2013-02-08 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT01465997 | Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older | Phase 3 | 551 | 2017-08-02 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT01954121 | Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures | Phase 3 | 436 | 2016-08-11 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT00438451 | Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs | Phase 4 | 361 | 2013-02-28 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT00807989 | The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy | Phase 4 | 207 | 2015-05-29 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT01127256 | Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation | Phase 4 | 200 | 2012-07-26 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT01128959 | Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy | Phase 3 | 108 | 2016-12-05 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT02870283 | Cost- Effectiveness and Quality of Life Assessment in Mood Disorder | Phase 4 | 107 | 2020-09-02 | carbamazepine | Its name | ClinicalTrials.gov |
| NCT00621751 | Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression | 70 | 2021-08-19 | carbamazepine | Its name | ClinicalTrials.gov |
1 to 10 of 129
See all 129 trialsComparisons in its trials31
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects Who Withdraw From the Study Due to a Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks) | 47 of 444 | 69 of 442 | 886 | NCT01243177 | Trial comparisons |
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks) | 328 of 444 | 332 of 442 | 886 | NCT01243177 | Trial comparisons |
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE) During the Treatment Phase (up to 113 Weeks) | 32 of 444 | 43 of 442 | 886 | NCT01243177 | Trial comparisons |
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): serious adverse events | 36 of 444 | 46 of 442 | 886 | NCT01243177 | Trial comparisons |
| Zonisamide vs Carbamazepine: serious adverse events | 15 of 281 | 17 of 300 | 581 | NCT00477295 | Trial comparisons |
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects Who Withdrew From the Study Due to a Treatment-emergent Adverse Event (AE) During the Treatment Phase (Maximum 3.5 Years) | 12 of 279 | 21 of 269 | 548 | NCT01465997 | Trial comparisons |
| Lacosamide (SS) vs Carbamazepine-Controlled Release (CBZ-CR) (SS): Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (Maximum of 3.5 Years) | 181 of 279 | 182 of 269 | 548 | NCT01465997 | Trial comparisons |
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE) During the Treatment Phase (Maximum of 3.5 Years) | 32 of 279 | 22 of 269 | 548 | NCT01465997 | Trial comparisons |
| Lacosamide (SS) vs Carbamazepine-Controlled Release (CBZ-CR) (SS): serious adverse events | 32 of 279 | 22 of 269 | 548 | NCT01465997 | Trial comparisons |
| Levetiracetam (Safety Set) vs Carbamazepine-IR (Safety Set): serious adverse events | 9 of 218 | 11 of 215 | 433 | NCT01954121 | Trial comparisons |
1 to 10 of 31
See all 31 comparisons in its trialsPapers from its trials53
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL108
GET https://conductscience.org/api/drugs/v1/CHEMBL108/trials?page=2